Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Eupraxia Pharmaceuticals Inc T.EPRX

Alternate Symbol(s):  EPRX | T.EPRX.W | T.EPRX.W.A

Healthcare Biotechnology
Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release alternatives to approved drugs. The Company’s principal business is the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidate, EP-104IAR, is designed to meet the unmet... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSX:EPRX)

Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

PR Newswire April 11, 2024

Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference

PR Newswire April 8, 2024

Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today

PR Newswire April 5, 2024

Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024

PR Newswire April 3, 2024

Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results

PR Newswire April 1, 2024

Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million

GlobeNewswire March 15, 2024

Canadian Investment Regulatory Organization Trade Resumption - EPRX

Canada NewsWire March 12, 2024

Eupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering of $30 Million

GlobeNewswire March 12, 2024

Eupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approximately $30 Million

GlobeNewswire March 11, 2024
View More News ››

Opinion & Analysis (TSX:EPRX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSX:EPRX)

Target price

  Raymond James target price is $18.00.
1northumberland - March 13, 2024

Raymond James - Lead Broker on Deal

Lets see if this US based brokerage can get the stock over issue
BeyondValuez - March 12, 2024

Someone doesn’t like something ?

Small amounts being dumped on alternate exchanges makes today look even worse. Not sure why?
Jmark1 - October 30, 2023

destruction

EPRX CFO was at Tekmira which held the delivery technology for the RNAi vaccines Tekmira is now Arbutus we are talking about the delivery...
kindvalue - August 17, 2021
View more Bullboard ››

Calima Energy Ord Shs

Calima Energy Ord Shs

Calima Energy Limited is an Australia-based production-focused energy company. The Company is engaged in the exploration and ...
View More »